MedTrace Logo

STEEL Percutaneous Coronary Intervention

NCT02327624 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-01-23

No results posted yet for this study

Summary

The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients undergoing elective Percutaneous Coronary Intervention (PCI) for stable Coronary artery disease (CAD).

Conditions

Interventions

DRUG

Clopidogrel

Compare Clopidogrel to two doses of Ticagrelor 60 and 90

DRUG

Ticagrelor 60

Compare Clopidogrel to two doses of Ticagrelor 60 and 90

DRUG

Ticagrelor 90

Compare Clopidogrel to two doses of Ticagrelor 60 and 90

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sheffield Teaching Hospitals NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327624 on ClinicalTrials.gov